Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers
- Written by Auzzi Shopping
- 87% of respondents deemed mRNA a key modality for the future
- More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand
- Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption
Read more: Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers